The agency said there had been “significant” manufacturing violations at the facility.
The FDA alleged that staff had retested materials after those items had failed initial tests “in order to produce acceptable findings”.
Other Ranbaxy units have also come under scrutiny by the US in the past.
The FDA has previously banned products from the company’s facilities in Paonta Sahib, Dewas and Mohali.
“We are taking swift action to prevent substandard-quality products from reaching US consumers,” Carol Bennett, acting director of the FDA’s Office of Compliance, said in a statement.
Ranbaxy said in a statement that it had “voluntarily and proactively suspended shipments” from the facility to the US after it received the inspection findings earlier this month.
“This development is clearly unacceptable and an appropriate management action will be taken upon completion of the internal investigation,” said Arun Sawhney, chief executive of Ranbaxy.
Ranbaxy’s shares fell as much as 20% on the FDA ruling.
lNTyUkrHFkYThree Indian nationals have been arrested and charged over the killing of Sikh separatist leader…
President Joe Biden has urged pro-Palestinian protesters on university campuses to uphold the rule of…
Blue Ivy Carter has joined the voice cast of The Lion King prequel Mufasa: The…
At least five people, including a four-month-old baby, have been killed after dozens of tornadoes…
Harvey Weinstein has been hospitalized just days after his 2020 rape conviction in New York…
Hamas has published a video showing the first proof of life of US and Israeli…